This course is part of the RCOG Core Knowledge series.
Ovarian cancer is the sixth most frequently diagnosed cancer in women, with around 7,300 new cases diagnosed in the UK during 2013. Fallopian tube and primary peritoneal cancers are considered within the 'ovarian cancer' group and managed with the same form of treatments. Many 'high grade serous' ovarian cancers are now recognised as actually arising from the terminal end of the fallopian tube, rather than the ovary itself.
Most ovarian cancers are sporadic although there is a genetic predisposition in about 10-15%. Treatment most commonly combines surgery and chemotherapy. Some early-stage disease will not require adjuvant chemotherapy. In advanced disease (stage 3 and 4), relapse is common reflected in the 5-year survival patterns of about 40%.
When you have completed this course, you will be able to:
- have a general understanding of 'ovarian/fallopian tube/peritoneal' cancers
- understand the important issues, regarding treatment strategies
- have the knowledge as to the important diagnostic tests required
- understand the assessments required in patient follow up to aid detection of recurrence.
Sean Kehoe (2013, 2019)
Professor Sean Kehoe FRCOG is a clinical academic managing the treatment of gynaecological cancers and precancers in women. He has over 20 years' experience in these areas. His clinical work is based at City Hospital in Birmingham.
This course is intended to help clinicians gain core knowledge for O&G training and the MRCOG examinations. It can also be used by O&G consultants to refresh their knowledge of the area or for teaching.
Product Details:
Product Name
Price
Malignant disease of the ovary and fallopian tube - 12 Month Access
£50.40
Login to purchase
| Product Name | Price | |
| Malignant disease of the ovary and fallopian tube - 12 Month Access | £50.40 | Login to purchase |